-
公开(公告)号:US20160368905A1
公开(公告)日:2016-12-22
申请号:US15141556
申请日:2016-04-28
Applicant: AbbVie Inc.
Inventor: David A. Betebenner , John K. Pratt , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Douglas K. Hutchinson , Warren M. Kati , Allan C. Krueger , Kenton L. Longenecker , Clarence J. Maring , John T. Randolph , Todd W. Rockway , Michael D. Tufano , Rolf Wagner , Dachun Liu
IPC: C07D409/10 , A61K31/513 , C07D213/64 , A61K31/4418 , C07C311/08 , A61K31/18 , C07D233/72 , A61K31/4166 , A61K31/27 , C07D263/24 , A61K31/421 , C07D239/10 , C07D207/27 , A61K31/402 , C07D405/10 , C07D403/10 , A61K45/06 , A61K31/425 , C07D275/02 , C07D239/54
CPC classification number: C07D409/10 , A61K31/18 , A61K31/27 , A61K31/402 , A61K31/4166 , A61K31/421 , A61K31/425 , A61K31/4418 , A61K31/503 , A61K31/513 , A61K45/06 , C07C311/08 , C07D207/27 , C07D213/64 , C07D233/32 , C07D233/72 , C07D239/10 , C07D239/54 , C07D263/22 , C07D263/24 , C07D275/02 , C07D403/10 , C07D405/10 , Y02P20/55
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Abstract translation: 本发明涉及:(a)特别是抑制HCV的化合物及其盐; (b)可用于制备这些化合物和盐的中间体; (c)包含这些化合物和盐的组合物; (d)制备这种中间体,化合物,盐和组合物的方法; (e)使用这些化合物,盐和组合物的方法; 和(f)包含这些化合物,盐和组合物的试剂盒。
-
公开(公告)号:US20160331749A1
公开(公告)日:2016-11-17
申请号:US15216855
申请日:2016-07-22
Applicant: AbbVie Inc.
Inventor: Andrew Bogdan , Warren M. Kati , Keith F. McDaniel , Chang H. Park , George S. Sheppard , Le Wang
IPC: A61K31/506 , A61K31/4433 , A61K31/497 , A61K31/444 , A61K31/4709 , A61K31/4412 , A61K31/4439
CPC classification number: A61K31/506 , A61K31/4412 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/497 , C07D211/86 , C07D213/69 , C07D401/04 , C07D401/12 , C07D405/04 , C07D405/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D487/04
Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
Abstract translation: 其中Y1,Y2,R1,R2,R3,A1,A2,A3和A4具有说明书中定义的任何值及其药学上可接受的盐,其可用作治疗疾病和病症的试剂,包括 炎性疾病,癌症和艾滋病。 还提供了由一种或多种式(I)化合物组成的药物组合物。
-
公开(公告)号:US09249138B2
公开(公告)日:2016-02-02
申请号:US14017901
申请日:2013-09-04
Applicant: ABBVIE INC.
Inventor: David A. Degoey , Pamela L. Donner , Warren M. Kati , Charles W. Hutchins , Allan C. Krueger , John T. Randolph , Christopher E. Motter , Preethi Krishnan , Neeta C. Mistry , Tami J. Pilot-Matias , Sachin V. Patel , Xiaoyan Li , Todd N. Soltwedel , Lissa T. Nelson
IPC: C07D239/48 , C07D471/04
CPC classification number: C07D471/04 , C07D239/48
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号:US09139536B2
公开(公告)日:2015-09-22
申请号:US13838223
申请日:2013-03-15
Applicant: AbbVie Inc.
Inventor: Charles A. Flentge , Douglas K. Hutchinson , David A. Betebenner , David A. DeGoey , Pamela L. Donner , Warren M. Kati , Allan C. Krueger , Dachun Liu , Yaya Liu , Kenton L. Longenecker , Clarence J. Maring , Christopher E. Motter , John K. Pratt , John T. Randolph , Todd W. Rockway , Kent D. Stewart , Rolf Wagner , Shuang Chen , Yi Gao , Xiaochun Lou , Geoff G. Z. Zhang
IPC: A61K31/505 , C07D239/54 , C07D239/22 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K31/513 , A61K45/06
CPC classification number: C07D239/54 , A61K31/513 , A61K45/06 , C07D239/22 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K2300/00
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Abstract translation: 本发明涉及:(a)特别是抑制HCV的化合物及其盐; (b)可用于制备这些化合物和盐的中间体; (c)包含这些化合物和盐的组合物; (d)制备这种中间体,化合物,盐和组合物的方法; (e)使用这些化合物,盐和组合物的方法; 和(f)包含这些化合物,盐和组合物的试剂盒。
-
公开(公告)号:US20150065542A1
公开(公告)日:2015-03-05
申请号:US14534916
申请日:2014-11-06
Applicant: ABBVIE INC.
Inventor: Allan C. Krueger , Warren M. Kati , Clarence J. Maring , Rolf Wagner , Charles W. Hutchins
IPC: C07D403/14 , C07D409/14
CPC classification number: C07D403/14 , C07D409/14
Abstract: The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.
Abstract translation: 本发明涉及抗HCV化合物,包含其的组合物以及使用该化合物治疗HCV感染的方法。
-
公开(公告)号:US20140294766A1
公开(公告)日:2014-10-02
申请号:US13838223
申请日:2013-03-15
Applicant: AbbVie Inc.
Inventor: Charles A. Flentge , Douglas K. Hutchinson , David A. Betebenner , David A. DeGoey , Pamela L. Donner , Warren M. Kati , Allan C. Krueger , Dachun Liu , Yaya Liu , Kenton L. Longenecker , Clarence J. Maring , Christopher E. Motter , John K. Pratt , John T. Randolph , Todd W. Rockway , Kent D. Stewart , Rolf Wagner , Shuang Chen , Yi Gao , Xiaochun Lou , Geoff G.Z. Zhang
IPC: C07D239/54 , A61K45/06 , A61K31/513
CPC classification number: C07D239/54 , A61K31/513 , A61K45/06 , C07D239/22 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K2300/00
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Abstract translation: 本发明涉及:(a)特别是抑制HCV的化合物及其盐; (b)可用于制备这些化合物和盐的中间体; (c)包含这些化合物和盐的组合物; (d)制备这种中间体,化合物,盐和组合物的方法; (e)使用这些化合物,盐和组合物的方法; 和(f)包含这些化合物,盐和组合物的试剂盒。
-
-
-
-
-